Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Male or female patient ≥ 18 years of age~2. Histologically or cytologically confirmed non-squamous NSCLC~3. EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR small molecule tyrosine kinase inhibitor~4. Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must have progressed on or had intolerance to an ALK inhibitor;~5. No prior adjuvant chemotherapy within 1 year of the first treatment day if there is recurrent disease~6. At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum life expectancy of ≥ 3 months~8. Adequate bone marrow, renal and liver function~Main Exclusion Criteria:~1. Histologic evidence of predominantly squamous cell NSCLC~2. Brain metastasis and/or leptomeningeal disease (known or suspected)~3. Peripheral neuropathy \> CTCAE grade 1~4. Possibility of a curative local treatment (surgery and/or radiotherapy)~5. Previous chemotherapy except adjuvant treatment with progression of disease documented ≥ 12 months after end of adjuvant treatment~6. Having received treatment in another clinical study within the 30 days prior to commencing study treatment or having side effects of a prior study drug that are not recovered to grade ≤ 1 or baseline, except for alopecia~7. Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed and Carboplatin plus L-DOS47 (Type: EXPERIMENTAL): Patients will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort for the first and last two dosing cohorts, and a minimum of 1 and a maximum of 2 patients for the middle three dosing cohorts. The starting dose of L-DOS47 will be 0.59 µg/kg; further planned dose levels to be assessed are 0.78, 1.5, 3.0, 6.0, 9.0 and 12.0 µg/kg. The standard of care doses of pemetrexed \[500 mg/m2\] and carboplatin \[AUC6\], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).